AbbVie this week acquired Celsius Therapeutics, whose focus is on “pioneering new precision medicines in inflammatory disease by harnessing the power of single-cell RNA sequencing and human biology at scale.” AbbVie acquired all outstanding Celsius equity for $250 million in cash.  “AbbVie shares our excitement about the potential of TREM1…

Results of a collaborative study between the Francis Crick Institute, London, and Aalborg University in Copenhagen have shown that there are measurable markers in the blood that can be detected up to eight years before a diagnosis of an inflammatory bowel disease (IBD). The researchers say their findings show that…

Sanofi and Teva Pharmaceuticals yesterday announced a collaboration to co-develop and co-commercialize TEV’574, a TL1A inhibitor currently in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn’s disease, two types of inflammatory bowel disease (IBD). The deal is worth potentially $1.5B overall, with $500M upfront.  Teva Pharmaceuticals is…

According to a new study from the Yale University School of Medicine, genotoxic metabolites present in patients with inflammatory bowel disease (IBD) may play a role in the development of colorectal cancer. The authors of the study, published in the journal Science, discovered a family of genotoxins called indolimines, that…

Crohn’s disease and ulcerative colitis, collectively referred to as Inflammatory bowel disease (IBD), are characterized by their prolonged inflammation of the gastrointestinal tract. IBD has been shown to lead to the development of colorectal tumors. In order to better understand the pathogenesis of IBD and the incidence of colorectal tumors,…

Scientists at Ben-Gurion University of the Negev (BGU) report that they are developing a novel therapeutic strategy for treating Inflammatory Bowel Diseases (IBDs) by sequestering inflammation-inducing molecules secreted by gut bacteria. The method, invented by Ehud Ohana, Ph.D., the department of clinical biochemistry and pharmacology at BGU, is based on…

A common antibody drug—infliximab—used to treat inflammatory bowel disease stops the body’s immune system from mounting a strong response to the SARS-CoV-2 virus, show results from a U.K. study. This finding means that patients treated with this drug may be more susceptible to prolonged or repeat cases of COVID-19 and…

Genetic associations between inflammatory bowel disease (IBD) and stress related to depression have been uncovered by a novel study that combined 3D genomic mapping with publicly available data from genome-wide association studies (GWAS). Carried out by researchers at Children’s Hospital of Philadelphia (CHOP), the study further implicated new genes involved…

Despite many treatments for inflammatory bowel disease (IBD), a number of patients fail to respond long-term. In a new study, a team of researchers led by scientists at the University of California, San Diego (UCSD), School of Medicine, reported that the lasting nature of IBD may be due to a…

A new whole-genome sequencing (WGS) study offers clues about the development of colon cancer in patients with inflammatory bowel disease (IBD).  Researchers found the rate of DNA change in cells affected by IBD was more than double that in healthy cells. The study also found that IBD-associated chronic inflammation disrupts…

PredictImmune said today it is partnering with the Crohn’s & Colitis Foundation to jointly fund and launch a clinical study designed to validate the company’s PredictSURE IBD biomarker, which if approved would be the first prognostic test for inflammatory bowel disease (IBD) authorized in the U.S. The PRECIOUS Study: Predicting…

Prometheus Biosciences said its bioinformatics platform and advanced machine learning techniques will be used by Takeda Pharmaceutical as part of a global collaboration to develop up to three targeted inflammatory bowel disease (IBD) therapeutics with companion diagnostics. The collaboration could generate up to $420 million for Prometheus in development, regulatory,…

Two independent sets of research published in Science Immunology have demonstrated how a subset of immune cells in the gut, known as group 3 innate lymphoid cells (ILC3), are tuned to the body’s daily circadian clock as they sense and interact with gut microbes. Collective results from the research indicate…

A multi-omic study of the microbiome by researchers from Harvard T.H. Chan School of Public Health and the Broad Institute of MIT and Harvard has provided a comprehensive view of functional dysbiosis in the gut microbiome during inflammatory bowel disease (IBD). The new study, by participants in the second phase…

Johnson & Johnson’s Janssen Research & Development will use BiomX's XMarker platform to discover microbiome-based biomarkers for inflammatory bowel disease (IBD), BiomX said today, through a collaboration whose value was not disclosed. Janssen R&D will apply XMarker to stratify responders and non-responders to IBD therapeutics, BiomX said, in an alliance…